Business
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
XanaMIA trial fully enrolled with final results expected in November 2026SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its expected completion in Nov
About this update from Actinogen Medical Limited
[{"type":"image","alt":"Actinogen Medical","displaySize":"","headline":null,"caption":"Actinogen Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQImuMTxtef96v4yTMESFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4","width":300,"height":300}},"lazy":false},{"type":"text","content":"XanaMIA trial fully enrolled with final results expected in November 2026","length":73,"tagName":"p"},{"type":"text","content":"SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its expected completion in November this year.","length":448,"tagName":"p"},{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In a confidential process designed to preserve the statistical power of the trial, the external DMC considered unblinded safety and efficacy data from approximately 37% of the expected final dataset, including 136 participants with one or more efficacy datapoints and 52 participants who had finished the full 36 weeks of treatment. All ACW staff and XanaMIA trial personnel remain blinded to participant treatment assignment","length":425,"tagName":"p"}]},{"val":[{"type":"text","content":"Following the positive DMC recommendation, the XanaMIA trial will continue to treat ongoing participants with either Xanamem® 10 mg or placebo for a total of 36 weeks – enrolment of the final 247th participant occurred in December last year and the last participant’s final evaluation visit is expected in September this year","length":325,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline final results are due in November of this year, with subsequent presentation at a key Alzheimer’s disease scientific meeting and publication in a peer-reviewed journal","length":175,"tagName":"p"}]},{"val":[{"type":"text","c...